nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP1A2—chronic obstructive pulmonary disease	0.343	1	CbGaD
Irbesartan—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.0588	0.156	CbGbCtD
Irbesartan—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.034	0.0903	CbGbCtD
Irbesartan—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0312	0.0831	CbGbCtD
Irbesartan—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0312	0.0831	CbGbCtD
Irbesartan—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0295	0.0784	CbGbCtD
Irbesartan—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0286	0.076	CbGbCtD
Irbesartan—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0286	0.076	CbGbCtD
Irbesartan—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0255	0.0677	CbGbCtD
Irbesartan—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.024	0.0637	CbGbCtD
Irbesartan—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0237	0.063	CbGbCtD
Irbesartan—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0162	0.0431	CbGbCtD
Irbesartan—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0154	0.0411	CbGbCtD
Irbesartan—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0138	0.0366	CbGbCtD
Irbesartan—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00808	0.0215	CbGbCtD
Irbesartan—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00763	0.0203	CbGbCtD
Irbesartan—JUN—respiratory system—chronic obstructive pulmonary disease	0.00137	0.0894	CbGeAlD
Irbesartan—EDNRA—bronchus—chronic obstructive pulmonary disease	0.00123	0.0806	CbGeAlD
Irbesartan—JUN—connective tissue—chronic obstructive pulmonary disease	0.0012	0.0787	CbGeAlD
Irbesartan—JUN—bronchus—chronic obstructive pulmonary disease	0.00113	0.0735	CbGeAlD
Irbesartan—EDNRA—trachea—chronic obstructive pulmonary disease	0.00111	0.0724	CbGeAlD
Irbesartan—JUN—smooth muscle tissue—chronic obstructive pulmonary disease	0.0011	0.072	CbGeAlD
Irbesartan—JUN—trachea—chronic obstructive pulmonary disease	0.00101	0.066	CbGeAlD
Irbesartan—AGTR1—connective tissue—chronic obstructive pulmonary disease	0.000907	0.0592	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00083	0.0542	CbGeAlD
Irbesartan—EDNRA—lung—chronic obstructive pulmonary disease	0.000796	0.052	CbGeAlD
Irbesartan—AGTR1—trachea—chronic obstructive pulmonary disease	0.000761	0.0497	CbGeAlD
Irbesartan—JUN—lung—chronic obstructive pulmonary disease	0.000726	0.0474	CbGeAlD
Irbesartan—Losartan—ACE—chronic obstructive pulmonary disease	0.000657	0.338	CrCbGaD
Irbesartan—JUN—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000556	0.253	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000556	0.253	CbGdCrCtD
Irbesartan—Valsartan—ALB—chronic obstructive pulmonary disease	0.000551	0.284	CrCbGaD
Irbesartan—AGTR1—lung—chronic obstructive pulmonary disease	0.000547	0.0357	CbGeAlD
Irbesartan—JUN—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000543	0.247	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000543	0.247	CbGdCrCtD
Irbesartan—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000523	0.0341	CbGeAlD
Irbesartan—Losartan—CYP1A2—chronic obstructive pulmonary disease	0.000466	0.24	CrCbGaD
Irbesartan—PTGS1—respiratory system—chronic obstructive pulmonary disease	0.000453	0.0296	CbGeAlD
Irbesartan—PTGS1—connective tissue—chronic obstructive pulmonary disease	0.000399	0.026	CbGeAlD
Irbesartan—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000365	0.0238	CbGeAlD
Irbesartan—PTGS1—trachea—chronic obstructive pulmonary disease	0.000335	0.0219	CbGeAlD
Irbesartan—CYP1A2—lung—chronic obstructive pulmonary disease	0.000278	0.0181	CbGeAlD
Irbesartan—Losartan—ALB—chronic obstructive pulmonary disease	0.000269	0.139	CrCbGaD
Irbesartan—PTGS1—lung—chronic obstructive pulmonary disease	0.00024	0.0157	CbGeAlD
Irbesartan—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00107	CcSEcCtD
Irbesartan—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00107	CcSEcCtD
Irbesartan—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.00017	0.00107	CcSEcCtD
Irbesartan—Infection—Formoterol—chronic obstructive pulmonary disease	0.000169	0.00106	CcSEcCtD
Irbesartan—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.00106	CcSEcCtD
Irbesartan—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00105	CcSEcCtD
Irbesartan—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000166	0.00105	CcSEcCtD
Irbesartan—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000166	0.00105	CcSEcCtD
Irbesartan—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00104	CcSEcCtD
Irbesartan—Infection—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00104	CcSEcCtD
Irbesartan—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00104	CcSEcCtD
Irbesartan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00104	CcSEcCtD
Irbesartan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00104	CcSEcCtD
Irbesartan—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000165	0.00104	CcSEcCtD
Irbesartan—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00103	CcSEcCtD
Irbesartan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000163	0.00103	CcSEcCtD
Irbesartan—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000163	0.00103	CcSEcCtD
Irbesartan—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.00103	CcSEcCtD
Irbesartan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000162	0.00102	CcSEcCtD
Irbesartan—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00101	CcSEcCtD
Irbesartan—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00101	CcSEcCtD
Irbesartan—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.001	CcSEcCtD
Irbesartan—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000159	0.001	CcSEcCtD
Irbesartan—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000159	0.001	CcSEcCtD
Irbesartan—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.001	CcSEcCtD
Irbesartan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000158	0.000996	CcSEcCtD
Irbesartan—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.000995	CcSEcCtD
Irbesartan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.000992	CcSEcCtD
Irbesartan—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.000987	CcSEcCtD
Irbesartan—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000157	0.000986	CcSEcCtD
Irbesartan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.000982	CcSEcCtD
Irbesartan—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000155	0.000978	CcSEcCtD
Irbesartan—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.000978	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000155	0.000976	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.000976	CcSEcCtD
Irbesartan—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000964	CcSEcCtD
Irbesartan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000153	0.000963	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000152	0.000956	CcSEcCtD
Irbesartan—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000152	0.000955	CcSEcCtD
Irbesartan—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000152	0.000955	CcSEcCtD
Irbesartan—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000151	0.000952	CcSEcCtD
Irbesartan—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000151	0.000952	CcSEcCtD
Irbesartan—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000945	CcSEcCtD
Irbesartan—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00015	0.000943	CcSEcCtD
Irbesartan—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.000943	CcSEcCtD
Irbesartan—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00015	0.000942	CcSEcCtD
Irbesartan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000149	0.000939	CcSEcCtD
Irbesartan—Injury—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000933	CcSEcCtD
Irbesartan—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000148	0.000932	CcSEcCtD
Irbesartan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000148	0.00093	CcSEcCtD
Irbesartan—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.000928	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.000925	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000147	0.000925	CcSEcCtD
Irbesartan—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000147	0.000923	CcSEcCtD
Irbesartan—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.000923	CcSEcCtD
Irbesartan—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000147	0.000923	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.000921	CcSEcCtD
Irbesartan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000145	0.000916	CcSEcCtD
Irbesartan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000145	0.000916	CcSEcCtD
Irbesartan—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000145	0.000916	CcSEcCtD
Irbesartan—Pain—Formoterol—chronic obstructive pulmonary disease	0.000145	0.000916	CcSEcCtD
Irbesartan—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000913	CcSEcCtD
Irbesartan—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000908	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000144	0.000906	CcSEcCtD
Irbesartan—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000144	0.000904	CcSEcCtD
Irbesartan—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.000901	CcSEcCtD
Irbesartan—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.000899	CcSEcCtD
Irbesartan—Pain—Montelukast—chronic obstructive pulmonary disease	0.000142	0.000897	CcSEcCtD
Irbesartan—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.000896	CcSEcCtD
Irbesartan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000142	0.000895	CcSEcCtD
Irbesartan—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.000891	CcSEcCtD
Irbesartan—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.00089	CcSEcCtD
Irbesartan—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000141	0.000887	CcSEcCtD
Irbesartan—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000141	0.000886	CcSEcCtD
Irbesartan—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000884	CcSEcCtD
Irbesartan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.000882	CcSEcCtD
Irbesartan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00014	0.000882	CcSEcCtD
Irbesartan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00014	0.000881	CcSEcCtD
Irbesartan—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.000879	CcSEcCtD
Irbesartan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000139	0.000877	CcSEcCtD
Irbesartan—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.000876	CcSEcCtD
Irbesartan—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000139	0.000876	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.000873	CcSEcCtD
Irbesartan—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000872	CcSEcCtD
Irbesartan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.000865	CcSEcCtD
Irbesartan—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.000865	CcSEcCtD
Irbesartan—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000136	0.000858	CcSEcCtD
Irbesartan—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.000851	CcSEcCtD
Irbesartan—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000135	0.000851	CcSEcCtD
Irbesartan—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.000847	CcSEcCtD
Irbesartan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.000847	CcSEcCtD
Irbesartan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000134	0.000847	CcSEcCtD
Irbesartan—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000134	0.000847	CcSEcCtD
Irbesartan—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000844	CcSEcCtD
Irbesartan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000134	0.000844	CcSEcCtD
Irbesartan—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000133	0.000837	CcSEcCtD
Irbesartan—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000133	0.000836	CcSEcCtD
Irbesartan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000133	0.000836	CcSEcCtD
Irbesartan—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000833	CcSEcCtD
Irbesartan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.000833	CcSEcCtD
Irbesartan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000132	0.000831	CcSEcCtD
Irbesartan—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000132	0.000831	CcSEcCtD
Irbesartan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000829	CcSEcCtD
Irbesartan—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000829	CcSEcCtD
Irbesartan—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000828	CcSEcCtD
Irbesartan—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000131	0.000827	CcSEcCtD
Irbesartan—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000812	CcSEcCtD
Irbesartan—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000803	CcSEcCtD
Irbesartan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000799	CcSEcCtD
Irbesartan—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000799	CcSEcCtD
Irbesartan—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.000789	CcSEcCtD
Irbesartan—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000125	0.000789	CcSEcCtD
Irbesartan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000125	0.000788	CcSEcCtD
Irbesartan—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000787	CcSEcCtD
Irbesartan—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000124	0.00078	CcSEcCtD
Irbesartan—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000123	0.000773	CcSEcCtD
Irbesartan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000122	0.000768	CcSEcCtD
Irbesartan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000122	0.000768	CcSEcCtD
Irbesartan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00012	0.000758	CcSEcCtD
Irbesartan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00012	0.000758	CcSEcCtD
Irbesartan—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000756	CcSEcCtD
Irbesartan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000119	0.000753	CcSEcCtD
Irbesartan—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000746	CcSEcCtD
Irbesartan—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.000745	CcSEcCtD
Irbesartan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000118	0.000742	CcSEcCtD
Irbesartan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000116	0.000733	CcSEcCtD
Irbesartan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000116	0.000733	CcSEcCtD
Irbesartan—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.000729	CcSEcCtD
Irbesartan—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000727	CcSEcCtD
Irbesartan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000115	0.000725	CcSEcCtD
Irbesartan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000114	0.000718	CcSEcCtD
Irbesartan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000114	0.000715	CcSEcCtD
Irbesartan—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.000711	CcSEcCtD
Irbesartan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.000708	CcSEcCtD
Irbesartan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000112	0.000708	CcSEcCtD
Irbesartan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00011	0.000694	CcSEcCtD
Irbesartan—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000693	CcSEcCtD
Irbesartan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00011	0.000692	CcSEcCtD
Irbesartan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000108	0.000681	CcSEcCtD
Irbesartan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000108	0.000681	CcSEcCtD
Irbesartan—Rash—Formoterol—chronic obstructive pulmonary disease	0.000107	0.000675	CcSEcCtD
Irbesartan—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000107	0.000675	CcSEcCtD
Irbesartan—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000107	0.000675	CcSEcCtD
Irbesartan—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000107	0.000675	CcSEcCtD
Irbesartan—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000674	CcSEcCtD
Irbesartan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000107	0.000671	CcSEcCtD
Irbesartan—Headache—Formoterol—chronic obstructive pulmonary disease	0.000107	0.000671	CcSEcCtD
Irbesartan—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.00067	CcSEcCtD
Irbesartan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.000669	CcSEcCtD
Irbesartan—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000669	CcSEcCtD
Irbesartan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000106	0.000667	CcSEcCtD
Irbesartan—Rash—Montelukast—chronic obstructive pulmonary disease	0.000105	0.000661	CcSEcCtD
Irbesartan—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000105	0.000661	CcSEcCtD
Irbesartan—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.000659	CcSEcCtD
Irbesartan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000104	0.000657	CcSEcCtD
Irbesartan—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000651	CcSEcCtD
Irbesartan—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000649	CcSEcCtD
Irbesartan—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000648	CcSEcCtD
Irbesartan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.000643	CcSEcCtD
Irbesartan—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000641	CcSEcCtD
Irbesartan—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000638	CcSEcCtD
Irbesartan—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000638	CcSEcCtD
Irbesartan—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000637	CcSEcCtD
Irbesartan—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000637	CcSEcCtD
Irbesartan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.000636	CcSEcCtD
Irbesartan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000101	0.000636	CcSEcCtD
Irbesartan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000633	CcSEcCtD
Irbesartan—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	9.92e-05	0.000625	CcSEcCtD
Irbesartan—Nausea—Montelukast—chronic obstructive pulmonary disease	9.89e-05	0.000623	CcSEcCtD
Irbesartan—Hypertension—Prednisolone—chronic obstructive pulmonary disease	9.74e-05	0.000614	CcSEcCtD
Irbesartan—Bradycardia—Prednisone—chronic obstructive pulmonary disease	9.59e-05	0.000604	CcSEcCtD
Irbesartan—Nausea—Salbutamol—chronic obstructive pulmonary disease	9.54e-05	0.000601	CcSEcCtD
Irbesartan—Discomfort—Prednisolone—chronic obstructive pulmonary disease	9.49e-05	0.000598	CcSEcCtD
Irbesartan—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	9.25e-05	0.000583	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	9.21e-05	0.00058	CcSEcCtD
Irbesartan—Oedema—Prednisolone—chronic obstructive pulmonary disease	9.21e-05	0.00058	CcSEcCtD
Irbesartan—Shock—Prednisolone—chronic obstructive pulmonary disease	9.06e-05	0.000571	CcSEcCtD
Irbesartan—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	8.99e-05	0.000566	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	8.9e-05	0.000561	CcSEcCtD
Irbesartan—Flushing—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000551	CcSEcCtD
Irbesartan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	8.54e-05	0.000538	CcSEcCtD
Irbesartan—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	8.51e-05	0.000536	CcSEcCtD
Irbesartan—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	8.41e-05	0.00053	CcSEcCtD
Irbesartan—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	8.27e-05	0.000521	CcSEcCtD
Irbesartan—Malnutrition—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.000516	CcSEcCtD
Irbesartan—Erythema—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.000516	CcSEcCtD
Irbesartan—Pain—Prednisolone—chronic obstructive pulmonary disease	7.87e-05	0.000496	CcSEcCtD
Irbesartan—Vision blurred—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000487	CcSEcCtD
Irbesartan—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	7.61e-05	0.000479	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	7.59e-05	0.000478	CcSEcCtD
Irbesartan—Anaemia—Prednisone—chronic obstructive pulmonary disease	7.58e-05	0.000477	CcSEcCtD
Irbesartan—Agitation—Prednisone—chronic obstructive pulmonary disease	7.53e-05	0.000475	CcSEcCtD
Irbesartan—Angioedema—Prednisone—chronic obstructive pulmonary disease	7.49e-05	0.000472	CcSEcCtD
Irbesartan—Malaise—Prednisone—chronic obstructive pulmonary disease	7.39e-05	0.000466	CcSEcCtD
Irbesartan—Vertigo—Prednisone—chronic obstructive pulmonary disease	7.37e-05	0.000464	CcSEcCtD
Irbesartan—Syncope—Prednisone—chronic obstructive pulmonary disease	7.35e-05	0.000463	CcSEcCtD
Irbesartan—Urticaria—Prednisolone—chronic obstructive pulmonary disease	7.31e-05	0.000461	CcSEcCtD
Irbesartan—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	7.21e-05	0.000454	CcSEcCtD
Irbesartan—Hypertension—Prednisone—chronic obstructive pulmonary disease	7.08e-05	0.000446	CcSEcCtD
Irbesartan—Arthralgia—Prednisone—chronic obstructive pulmonary disease	6.98e-05	0.00044	CcSEcCtD
Irbesartan—Myalgia—Prednisone—chronic obstructive pulmonary disease	6.98e-05	0.00044	CcSEcCtD
Irbesartan—Anxiety—Prednisone—chronic obstructive pulmonary disease	6.96e-05	0.000438	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	6.93e-05	0.000437	CcSEcCtD
Irbesartan—Discomfort—Prednisone—chronic obstructive pulmonary disease	6.9e-05	0.000434	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	6.78e-05	0.000427	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	6.69e-05	0.000421	CcSEcCtD
Irbesartan—Oedema—Prednisone—chronic obstructive pulmonary disease	6.69e-05	0.000421	CcSEcCtD
Irbesartan—Infection—Prednisone—chronic obstructive pulmonary disease	6.65e-05	0.000419	CcSEcCtD
Irbesartan—Shock—Prednisone—chronic obstructive pulmonary disease	6.58e-05	0.000415	CcSEcCtD
Irbesartan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	6.56e-05	0.000413	CcSEcCtD
Irbesartan—Tachycardia—Prednisone—chronic obstructive pulmonary disease	6.53e-05	0.000411	CcSEcCtD
Irbesartan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	6.5e-05	0.000409	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	6.47e-05	0.000407	CcSEcCtD
Irbesartan—Anorexia—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000402	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	6.1e-05	0.000384	CcSEcCtD
Irbesartan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	6.09e-05	0.000384	CcSEcCtD
Irbesartan—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	6.01e-05	0.000378	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	5.89e-05	0.000371	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	5.82e-05	0.000366	CcSEcCtD
Irbesartan—Rash—Prednisolone—chronic obstructive pulmonary disease	5.81e-05	0.000366	CcSEcCtD
Irbesartan—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	5.8e-05	0.000365	CcSEcCtD
Irbesartan—Fatigue—Prednisone—chronic obstructive pulmonary disease	5.77e-05	0.000363	CcSEcCtD
Irbesartan—Headache—Prednisolone—chronic obstructive pulmonary disease	5.77e-05	0.000363	CcSEcCtD
Irbesartan—Constipation—Prednisone—chronic obstructive pulmonary disease	5.72e-05	0.00036	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	5.51e-05	0.000347	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	5.47e-05	0.000345	CcSEcCtD
Irbesartan—Nausea—Prednisolone—chronic obstructive pulmonary disease	5.47e-05	0.000344	CcSEcCtD
Irbesartan—Urticaria—Prednisone—chronic obstructive pulmonary disease	5.32e-05	0.000335	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	5.29e-05	0.000333	CcSEcCtD
Irbesartan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	5.29e-05	0.000333	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	4.93e-05	0.000311	CcSEcCtD
Irbesartan—Asthenia—Prednisone—chronic obstructive pulmonary disease	4.8e-05	0.000302	CcSEcCtD
Irbesartan—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.73e-05	0.000298	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.58e-05	0.000288	CcSEcCtD
Irbesartan—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.42e-05	0.000279	CcSEcCtD
Irbesartan—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.25e-05	0.000268	CcSEcCtD
Irbesartan—Rash—Prednisone—chronic obstructive pulmonary disease	4.22e-05	0.000266	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.21e-05	0.000265	CcSEcCtD
Irbesartan—Headache—Prednisone—chronic obstructive pulmonary disease	4.19e-05	0.000264	CcSEcCtD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—IL6—chronic obstructive pulmonary disease	4.07e-05	0.000396	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.06e-05	0.000396	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.05e-05	0.000395	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.05e-05	0.000394	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	4.02e-05	0.000392	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.02e-05	0.000391	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4e-05	0.000389	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—chronic obstructive pulmonary disease	3.98e-05	0.000388	CbGpPWpGaD
Irbesartan—Nausea—Prednisone—chronic obstructive pulmonary disease	3.97e-05	0.00025	CcSEcCtD
Irbesartan—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.96e-05	0.000386	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	3.93e-05	0.000383	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CXCL8—chronic obstructive pulmonary disease	3.9e-05	0.00038	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—chronic obstructive pulmonary disease	3.9e-05	0.00038	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.82e-05	0.000372	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.82e-05	0.000372	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.78e-05	0.000368	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	3.77e-05	0.000367	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.75e-05	0.000365	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.72e-05	0.000363	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—EGFR—chronic obstructive pulmonary disease	3.71e-05	0.000362	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	3.7e-05	0.00036	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	3.69e-05	0.00036	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.69e-05	0.00036	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.69e-05	0.00036	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	3.69e-05	0.000359	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.68e-05	0.000358	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.67e-05	0.000358	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL6—chronic obstructive pulmonary disease	3.66e-05	0.000357	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.64e-05	0.000355	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.63e-05	0.000354	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—IL6—chronic obstructive pulmonary disease	3.62e-05	0.000353	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	3.62e-05	0.000353	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	3.62e-05	0.000353	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.55e-05	0.000346	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.53e-05	0.000344	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	3.52e-05	0.000343	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.52e-05	0.000343	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	3.51e-05	0.000342	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.5e-05	0.000341	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.48e-05	0.000339	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.48e-05	0.000339	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.47e-05	0.000339	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.47e-05	0.000338	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	3.46e-05	0.000337	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	3.46e-05	0.000337	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.45e-05	0.000336	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GC—chronic obstructive pulmonary disease	3.45e-05	0.000336	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	3.45e-05	0.000336	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	3.45e-05	0.000336	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—chronic obstructive pulmonary disease	3.44e-05	0.000335	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.43e-05	0.000334	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.39e-05	0.00033	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL6—chronic obstructive pulmonary disease	3.36e-05	0.000327	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.35e-05	0.000326	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.34e-05	0.000325	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GCLC—chronic obstructive pulmonary disease	3.31e-05	0.000322	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.3e-05	0.000321	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.24e-05	0.000315	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.22e-05	0.000314	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CRP—chronic obstructive pulmonary disease	3.21e-05	0.000313	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.21e-05	0.000313	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.18e-05	0.00031	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.18e-05	0.000309	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—VEGFA—chronic obstructive pulmonary disease	3.17e-05	0.000309	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—chronic obstructive pulmonary disease	3.17e-05	0.000309	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.15e-05	0.000307	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.13e-05	0.000305	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.11e-05	0.000303	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.1e-05	0.000302	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TLR4—chronic obstructive pulmonary disease	3.08e-05	0.0003	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	3.02e-05	0.000294	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CTGF—chronic obstructive pulmonary disease	3.02e-05	0.000294	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.01e-05	0.000293	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.99e-05	0.000291	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.98e-05	0.00029	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.95e-05	0.000287	CbGpPWpGaD
Irbesartan—JUN—Immune System—TLR2—chronic obstructive pulmonary disease	2.9e-05	0.000283	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL6—chronic obstructive pulmonary disease	2.9e-05	0.000283	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.88e-05	0.000281	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.84e-05	0.000277	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	2.82e-05	0.000274	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.78e-05	0.000271	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.78e-05	0.000271	CbGpPWpGaD
Irbesartan—JUN—Immune System—KL—chronic obstructive pulmonary disease	2.73e-05	0.000266	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.73e-05	0.000266	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.65e-05	0.000258	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.61e-05	0.000255	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.6e-05	0.000253	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.56e-05	0.000249	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.54e-05	0.000248	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.5e-05	0.000244	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.48e-05	0.000242	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.47e-05	0.00024	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.43e-05	0.000237	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.41e-05	0.000234	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.4e-05	0.000234	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—chronic obstructive pulmonary disease	2.4e-05	0.000233	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.36e-05	0.00023	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.32e-05	0.000226	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.31e-05	0.000225	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.29e-05	0.000223	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.29e-05	0.000223	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.28e-05	0.000222	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.27e-05	0.000221	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.27e-05	0.000221	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.26e-05	0.00022	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	2.23e-05	0.000217	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD8A—chronic obstructive pulmonary disease	2.2e-05	0.000214	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—IL6—chronic obstructive pulmonary disease	2.19e-05	0.000214	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.18e-05	0.000212	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.17e-05	0.000212	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.13e-05	0.000208	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.07e-05	0.000202	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB3—chronic obstructive pulmonary disease	2.05e-05	0.000199	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.02e-05	0.000197	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.02e-05	0.000197	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.01e-05	0.000196	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.96e-05	0.000191	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.95e-05	0.00019	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.9e-05	0.000185	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.89e-05	0.000184	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.88e-05	0.000183	CbGpPWpGaD
Irbesartan—JUN—Immune System—CRP—chronic obstructive pulmonary disease	1.87e-05	0.000182	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.86e-05	0.000182	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.86e-05	0.000182	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.86e-05	0.000181	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.85e-05	0.00018	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.83e-05	0.000178	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.81e-05	0.000177	CbGpPWpGaD
Irbesartan—JUN—Immune System—TLR4—chronic obstructive pulmonary disease	1.79e-05	0.000175	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.78e-05	0.000174	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.77e-05	0.000173	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.76e-05	0.000172	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.74e-05	0.000169	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.72e-05	0.000167	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.7e-05	0.000166	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.7e-05	0.000166	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.7e-05	0.000166	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.69e-05	0.000164	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.66e-05	0.000162	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.65e-05	0.000161	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.63e-05	0.000159	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.59e-05	0.000155	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.58e-05	0.000154	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.58e-05	0.000154	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.57e-05	0.000153	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.55e-05	0.000151	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.53e-05	0.000149	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.51e-05	0.000147	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.46e-05	0.000142	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.44e-05	0.00014	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ALB—chronic obstructive pulmonary disease	1.37e-05	0.000134	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.34e-05	0.000131	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.34e-05	0.000131	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.32e-05	0.000129	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—NOS3—chronic obstructive pulmonary disease	1.31e-05	0.000128	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.31e-05	0.000127	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.3e-05	0.000127	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.29e-05	0.000126	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.28e-05	0.000124	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.27e-05	0.000124	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.24e-05	0.000121	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.23e-05	0.00012	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.22e-05	0.000119	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.21e-05	0.000118	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	1.2e-05	0.000117	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.2e-05	0.000117	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.2e-05	0.000117	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.19e-05	0.000116	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.18e-05	0.000115	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—chronic obstructive pulmonary disease	1.17e-05	0.000114	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1B—chronic obstructive pulmonary disease	1.17e-05	0.000114	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.15e-05	0.000112	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.14e-05	0.000111	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.12e-05	0.000109	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.11e-05	0.000108	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	1.1e-05	0.000107	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.09e-05	0.000106	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.05e-05	0.000103	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.01e-05	9.86e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1e-05	9.75e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1e-05	9.74e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1e-05	9.74e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.91e-06	9.66e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	9.88e-06	9.63e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.81e-06	9.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	9.8e-06	9.55e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.52e-06	9.28e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.29e-06	9.05e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.13e-06	8.9e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	9.02e-06	8.79e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	8.94e-06	8.71e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—chronic obstructive pulmonary disease	8.89e-06	8.66e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.87e-06	8.64e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.55e-06	8.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.47e-06	8.25e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.44e-06	8.22e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	8.37e-06	8.16e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.32e-06	8.11e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.31e-06	8.1e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.24e-06	8.03e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—chronic obstructive pulmonary disease	8.23e-06	8.02e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.86e-06	7.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.85e-06	7.65e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.81e-06	7.61e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.76e-06	7.56e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	7.74e-06	7.54e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.69e-06	7.5e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	7.64e-06	7.44e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.54e-06	7.34e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	7.4e-06	7.21e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.35e-06	7.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.11e-06	6.93e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.93e-06	6.75e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.87e-06	6.69e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.83e-06	6.66e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—chronic obstructive pulmonary disease	6.83e-06	6.66e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.78e-06	6.6e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.54e-06	6.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	6.46e-06	6.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.46e-06	6.29e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.39e-06	6.22e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.37e-06	6.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.31e-06	6.15e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.04e-06	5.88e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.98e-06	5.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.91e-06	5.76e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	5.9e-06	5.74e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.87e-06	5.72e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.86e-06	5.71e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.79e-06	5.64e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.75e-06	5.6e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.43e-06	5.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.39e-06	5.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.11e-06	4.98e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	5e-06	4.87e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.83e-06	4.7e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	4.78e-06	4.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.53e-06	4.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.47e-06	4.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.42e-06	4.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.16e-06	4.06e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.1e-06	4e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	4.07e-06	3.96e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.95e-06	3.85e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.93e-06	3.82e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	3.89e-06	3.79e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	3.48e-06	3.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.33e-06	3.24e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.68e-06	2.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.57e-06	2.5e-05	CbGpPWpGaD
